Obama policy a lift for stem cell researchers
By Bernadette Tansey,
San Francisco Chronicle
| 11. 29. 2008
[ Quotes CGS's Jesse Reynolds ]
Stem cell research advocates have waited nearly eight years for the policy change President-elect Barack Obama has signaled he'll make in the early days of his administration: lifting the restrictions imposed by President Bush on federal funding for research on human embryonic stem cells.
Those limits, and earlier laws, have left stem cell labs hungering for support since the versatile human stem cells were first derived in 1998.
Such cells, often taken from extra embryos created by in vitro fertilization clinics, can morph into the specialized cells found in skin, nerves and many other tissues. Bush shared the moral objections of some religious groups and political conservatives to research on human embryos. However, the prospect of a powerful new cell replacement technology that could some day cure injury and disease has now shifted many Republicans as well as Democrats toward support for federal funding of the work.
But Obama, even if he changes the policy, may still be powerless to send much more money to stem cell researchers anytime soon because he will be taking office amid a historic global...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...